In patients with clinical heart failure and low B-type natriuretic peptide levels, the authors found these patients usually are young and obese, with higher ejection fraction and better renal function.
Using left ventricular peak systolic global longitudinal strain vs. left ventricular ejection fraction to survey patients undergoing potentially cardiotoxic chemotherapy with at least one other risk factor for heart failure showed no difference in the primary endpoint of the difference in ejection fraction between the two groups at one year.
A prespecified subgroup analysis of heart failure patients with reduced ejection fraction who were on neprilysin inhibitors before empagliflozin was administered (vs. those not on neprilysin inhibitors) showed the reduction in mortality and hospital admissions for heart failure were not attenuated by concurrent neprilysin use.
An analysis of renal outcomes in the PARAGON-HF trial revealed sacubitril/valsartan slows progression of kidney disease in patients with heart failure with preserved ejection fraction compared to valsartan alone.
Hospitals and subacute facilities monitor congestive heart failure patients closely, but there may be a gap in care once patients are discharged. A transitional heart failure care clinic can fill that gap.
This largest-to-date analysis of six randomized studies of ST-elevation myocardial infarction revealed no association between body mass index and infarct size, one-year mortality, or heart failure hospitalization.
A comprehensive cardiorespiratory study of stable systolic heart failure patients showed Cheyne-Stokes breathing in the awake, upright position is related to hypercapnia and is independently associated with a higher risk of cardiac death.